Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression

The activity of both serum and effector cell antibody-dependent cellular cytotoxicity (ADCC) against human immunodeficiency virus (HIV-1, HIV) was assessed in HIV-infected individuals. The goal was to relate ADCC levels with the stage or progression of HIV disease. Serial serum samples, usually coll...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical immunology 1989-11, Vol.9 (6), p.454-461
Main Authors: OJO-AMAIZE, E, NISHANIAN, P. G, HEITJAN, D. F, REZAI, A, ESMAIL, I, KORNS, E, DETELS, R, FAHEY, J, GIORGI, J. V
Format: Article
Language:English
Subjects:
Analysis of Variance
Antibody-Dependent Cell Cytotoxicity - immunology
Biological and medical sciences
CD4-Positive T-Lymphocytes - immunology
Cohort Studies
Cytotoxicity Tests, Immunologic
HIV - immunology
HIV Antibodies - biosynthesis
HIV Antibodies - immunology
HIV Infections - epidemiology
HIV Infections - immunology
HIV Seropositivity - immunology
HIV-1 - immunology
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Leukocyte Count
Leukocytes, Mononuclear - immunology
Los Angeles - epidemiology
Male
Medical sciences
Multicenter Studies as Topic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The activity of both serum and effector cell antibody-dependent cellular cytotoxicity (ADCC) against human immunodeficiency virus (HIV-1, HIV) was assessed in HIV-infected individuals. The goal was to relate ADCC levels with the stage or progression of HIV disease. Serial serum samples, usually collected at 6-month intervals, from individuals at defined stages of HIV disease (seroconversion, the HIV-seropositive period before AIDS, and around the time of clinical AIDS diagnosis) were tested. HIV-coated CEM tumor cells were used as targets. Effector-cell ADCC activity was evaluated using fresh peripheral blood mononuclear cells (PBMC) from HIV-infected individuals at different stages of HIV disease. Samples were obtained from male homosexual participants in the Multicenter AIDS Cohort Study (MACS). In seroconverters, ADCC-inducing HIV-specific antibodies were detected at the time that the ELISA antibody test was first positive. Within several months, serum ADCC activity stabilized in each individual. In 29 HIV-seroprevalent individuals (HIV seropositive on their first visit), serum ADCC activity remained constant regardless of whether the individual's HIV disease was stable (high stable CD4; n = 9) or rapidly deteriorating (sharply declining CD4, n = 10; AIDS progressors, n = 10). With respect to effector-cell activity, PBMC from HIV-infected individuals with or without AIDS were capable of mediating ADCC with heterologous and usually with autologous sera. Although the level of NK cytotoxic activity and the level of antibody-armed effector cell activity have been reported to decline as disease progresses, our results support previous observations that ADCC effector-cell activity against antibody-coated targets does not decline in HIV infection.
ISSN:0271-9142
1573-2592
DOI:10.1007/BF00918014